Rhone Ma Holdings BhdXKLS:5278 59 PEG Ratio is 6.85 as of Jul. 08, 2026, which is 40% below its 10-year median of 11.40. GuruFocus rates XKLS:5278 with a GF Score™ of 59/100 and a GF Value™ of RM0.80 (Modestly Undervalued). Among 350 Drug Manufacturers companies, Rhone Ma Holdings Bhd ranks worse than 84.86% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Rhone Ma Holdings Bhd's PEG Ratio or its related term are showing as below:
XKLS:5278'
s PEG Ratio Range Over the Past 10 Years
Min: 2.48 Med: 11.4 Max: 67.31
Current: 6.85
During the past 13 years, Rhone Ma Holdings Bhd's highest PEG Ratio was 67.31. The lowest was 2.48. And the median was 11.40.
XKLS:5278's PEG Ratio is ranked worse than 84.86% of 350
companies
in the Drug Manufacturers industry
Industry Median: 1.725
vs XKLS:5278: 6.85
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Rhone Ma Holdings Bhd (XKLS:5278) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:5278 vs ZTS, UTHR, VTRS: PEG Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rhone Ma Holdings Bhd's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhone Ma Holdings Bhd PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rhone Ma Holdings Bhd's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Rhone Ma Holdings Bhd's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Rhone Ma Holdings Bhd (XKLS:5278) has a PEG Ratio of 6.85 as of Jul. 08, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Rhone Ma Holdings Bhd and its competitors. This is 40% below median its historical median of 11.40. Over the past decade, Rhone Ma Holdings Bhd's PEG Ratio has ranged from 2.48 to 67.31. According to the industry distribution chart, Rhone Ma Holdings Bhd ranks #297 out of 350 companies in the Drug Manufacturers industry, placing it in the top 84.9%.
Is Rhone Ma Holdings Bhd's PEG Ratio too high?
Rhone Ma Holdings Bhd's current PEG Ratio of 6.85 is 40% below median its 10-year median of 11.40. Over the past 10 years, this metric has ranged from a low of 2.48 to a high of 67.31. The Drug Manufacturers industry median PEG Ratio is 1.73. Rhone Ma Holdings Bhd's value of 6.85 is 297.1% above this industry median. Based on the distribution chart, Rhone Ma Holdings Bhd ranks #297 out of 350 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Rhone Ma Holdings Bhd has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rhone Ma Holdings Bhd's PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Rhone Ma Holdings Bhd ranks #297 out of 350 companies for PEG Ratio. This places Rhone Ma Holdings Bhd in the lower half of its industry. The industry median PEG Ratio is 1.73. Rhone Ma Holdings Bhd's value of 6.85 is 297.1% above this benchmark. Historically, Rhone Ma Holdings Bhd's own PEG Ratio has ranged from 2.48 to 67.31 over the past decade. While the company's 10-year median is 11.40 vs. the industry median of 1.73, Rhone Ma Holdings Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.73, based on 350 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rhone Ma Holdings Bhd's current PEG Ratio of 6.85 is 297.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Rhone Ma Holdings Bhd and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhone Ma Holdings Bhd's current PEG Ratio is 6.85, which is 40% below median its own 10-year median of 11.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhone Ma Holdings Bhd stock overvalued right now?
Based on GuruFocus' analysis, Rhone Ma Holdings Bhd (XKLS:5278) is currently considered Modestly Undervalued. The stock's GF Value™ is RM0.80, compared to a current price of RM0.69 — trading 13.8% below its estimated fair value. The current PEG Ratio is 6.85, which is 40% below median its 10-year median of 11.40 and 297.1% above the Drug Manufacturers industry median of 1.73. Rhone Ma Holdings Bhd's overall GF Score™ is 59/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Rhone Ma Holdings Bhd (XKLS:5278), the current PEG Ratio is 6.85 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rhone Ma Holdings Bhd (XKLS:5278) Overvalued in 2026?
Based on GuruFocus' analysis, Rhone Ma Holdings Bhd stock appears to be undervalued.
The current stock price of RM0.69 is trading 13.8% below its estimated GF Value™ of RM0.80.
GuruFocus considers Rhone Ma Holdings Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:5278:
PEG Ratio: 6.85 (40% below median its 10-year median of 11.40)
GF Value™: RM0.80 vs. price of RM0.69 (13.8% below fair value)
Industry Position: 297.1% above the Drug Manufacturers median (#297 of 350)
No single metric tells the full story. See the XKLS:5278 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rhone Ma Holdings Bhd, along with its subsidiaries, is mainly involved in the provision of end-to-end animal health solutions. The Group provides veterinary consultation services, diagnostic laboratory analyses, R&D, and is engaged in the manufacturing and distribution of animal health products. Its reportable segments are: Animal health products and equipment, Food ingredients, and Others. The majority of its revenue is generated from the Animal health products and equipment segment, which is engaged in marketing, trading, distribution, and manufacturing of animal health products and equipment, such as pharmaceuticals, vaccines, feed additives, pesticides, and others. Geographically, the Group's operations are predominantly located in Malaysia.
59GF Score
Get the complete analysis for XKLS:5278
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:5278 has been successfully added to your 
